Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | DBH | P09172 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4254406 | 0.88 | AKR1B1 (0.43) | PTGDR2DBHP2RX7 | |
| SCHEMBL4254345 | 0.84 | PTGDR2 (0.42) | MAPTTP53PTGDR2DBH | |
| SCHEMBL4260018 | 0.84 | TP53 (0.48) | MAPTTP53PTGDR2THRB | |
| SCHEMBL4254919 | 0.83 | TSHR (0.39) | MAPTTP53PTGDR2ADAMTS5THRB | |
| SCHEMBL4257022 | 0.83 | TP53 (0.39) | MAPTTP53PTGDR2ADAMTS5THRB | |
| SCHEMBL4259885 | 0.82 | ADAMTS5 (0.52) | MAPTTP53ADAMTS5ALDH1A1 | |
| SCHEMBL4976844 | 0.82 | KMT2A (0.38) | MAPTPTGDR2DBHP2RX7 | |
| SCHEMBL4258971 | 0.81 | TP53 (0.45) | MAPTTP53PTGDR2ADAMTS5THRB | |
| SCHEMBL4262087 | 0.81 | ADAMTS5 (0.41) | MAPTTP53PTGDR2ADAMTS5THRB | |
| SCHEMBL4267172 | 0.80 | CHRM5 (0.42) | MAPTTP53PTGDR2ADAMTS5THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | claimed |
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV2, TRPV3 | MAPT 3349/4885TP53 3194/4885PTGDR2 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.